Patents by Inventor Manuel Grez

Manuel Grez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INHIBITORS OF NHR2 AND/OR RUNX1/ETO-TETRAMERIZATION
    Publication number: 20210147415
    Abstract: The invention relates to inhibitors of the NHR2 tetramerization and their use as tumor therapeutics (e.g. against acute myeloid leukemia (AML)), cytostatics, and diagnostic agents.
    Type: Application
    Filed: November 6, 2020
    Publication date: May 20, 2021
    Inventors: Alexander Metz, Holger Gohlke, Julia Schanda, Christian Wichmann, Manuel Grez
  • CAR-expressing NK-92 cells as cell therapeutic agents
    Patent number: 10550197
    Abstract: The present invention relates to an ErbB2-specific NK-92 cell or cell line containing a lentiviral vector encoding a chimeric antigen receptor and preferably two vector integration loci in its cellular genome. The present invention further relates to the use of the ErbB2-specific NK-92 cell or cell line in the prevention and/or treatment of cancer, preferably ErbB2-expressing cancers. The present invention further relates to the use of the ErbB2-specific NK-92 cell or cell line as targeted cell therapeutic agent and/or for adoptive cancer immunotherapy. The present invention further relates to a method for generating an ErbB2-specific NK-92 cell or cell line as well as to a method for identifying an ErbB2-specific NK-92 cell or cell line and to the ErbB2-specific NK-92 cell or cell line obtained or identified by the methods as well as their uses.
    Type: Grant
    Filed: June 18, 2015
    Date of Patent: February 4, 2020
    Assignees: Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus, DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH
    Inventors: Winfried Wels, Kurt Schonfeld, Torsten Tonn, Manuel Grez, Congcong Zhang
  • CAR-EXPRESSING NK-92 CELLS AS CELL THERAPEUTIC AGENTS
    Publication number: 20180282427
    Abstract: The present invention relates to an ErbB2-specific NK-92 cell or cell line containing a lentiviral vector encoding a chimeric antigen receptor and preferably two vector integration loci in its cellular genome. The present invention further relates to the use of the ErbB2-specific NK-92 cell or cell line in the prevention and/or treatment of cancer, preferably ErhB2-expressing cancers. The present invention further relates to the use of the ErbB2-specific NK-92 cell or cell line as targeted cell therapeutic agent and/or for adoptive cancer immunotherapy. The present invention further relates to a method for generating an ErbB2-specific NK-92 cell or cell line as well as to a method for identifying au ErbB2-specific NK-92 cell or cell line and to the ErbB2-specific NK-92 cell or cell line obtained or identified by the methods as well as their uses.
    Type: Application
    Filed: February 20, 2018
    Publication date: October 4, 2018
    Applicants: CHEMOTHERAPEUTISCHES FORSCHUNGSINSTITUT GEORG-SPEYER-HAUS, DRK BLUTSPENDEDIENST BADEN-WURTTEMBERG-HESSEN GGMBH
    Inventors: Winfried Wels, Kurt Schonfeld, Torsten Tonn, Manuel Grez, Congcong Zhang
  • INHIBITORS OF NHR2 AND/OR RUNX1/ETO-TETRAMERIZATION
    Publication number: 20180230143
    Abstract: The invention relates to inhibitors of the NHR2 tetramerization and their use as tumor therapeutics (e.g. against acute myeloid leukemia (AML)), cytostatics, and diagnostic agents.
    Type: Application
    Filed: December 11, 2017
    Publication date: August 16, 2018
    Inventors: Alexander Metz, Holger Gohlke, Julia Schanda, Christian Wichmann, Manuel Grez
  • Car-expressing NK-92 cells as cell therapeutic agents
    Patent number: 9920132
    Abstract: The present invention relates to an ErbB2-specific NK-92 cell or cell line containing a lentiviral vector encoding a chimeric antigen receptor and preferably two vector integration loci in its cellular genome. The present invention further relates to the use of the ErbB2-specific NK-92 cell or cell line in the prevention and/or treatment of cancer, preferably ErbB2-expressing cancers. The present invention further relates to the use of the ErbB2-specific NK-92 cell or cell line as targeted cell therapeutic agent and/or for adoptive cancer immunotherapy. The present invention further relates to a method for generating an ErbB2-specific NK-92 cell or cell line as well as to a method for identifying an ErbB2-specific NK-92 cell or cell line and to the ErbB2-specific NK-92 cell or cell line obtained or identified by the methods as well as their uses.
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: March 20, 2018
    Assignees: Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus, DRK Blutspendedienst Baden-Wurttemberg-Hessen gGmbH
    Inventors: Winfried Wels, Kurt Schonfeld, Torsten Tonn, Manuel Grez, Congcong Zhang
  • CAR-EXPRESSING NK-92 CELLS AS CELL THERAPEUTIC AGENTS
    Publication number: 20170283507
    Abstract: The present invention relates to an ErbB2-specific NK-92 cell or cell line containing a lentiviral vector encoding a chimeric antigen receptor and preferably two vector integration loci in its cellular genome. The present invention further relates to the use of the ErbB2-specific NK-92 cell or cell line in the prevention and/or treatment of cancer, preferably ErbB2-expressing cancers. The present invention further relates to the use of the ErbB2-specific NK-92 cell or cell line as targeted cell therapeutic agent and/or for adoptive cancer immunotherapy. The present invention further relates to a method for generating an ErbB2-specific NK-92 cell or cell line as well as to a method for identifying an ErbB2-specific NK-92 cell or cell line and to the ErbB2-specific NK-92 cell or cell line obtained or identified by the methods as well as their uses.
    Type: Application
    Filed: May 19, 2017
    Publication date: October 5, 2017
    Inventors: Winfried Wels, Kurt Schonfeld, Torsten Tonn, Manuel Grez, Congcong Zhang
  • CAR-EXPRESSING NK-92 CELLS AS CELL THERAPEUTIC AGENTS
    Publication number: 20170129967
    Abstract: The present invention relates to an ErbB2-specific NK-92 cell or cell line containing a lentiviral vector encoding a chimeric antigen receptor and preferably two vector integration loci in its cellular genome. The present invention further relates to the use of the ErbB2-specific NK-92 cell or cell line in the prevention and/or treatment of cancer, preferably ErbB2-expressing cancers. The present invention further relates to the use of the ErbB2-specific NK-92 cell or cell line as targeted cell therapeutic agent and/or for adoptive cancer immunotherapy. The present invention further relates to a method for generating an ErbB2-specific NK-92 cell or cell line as well as to a method for identifying an ErbB2-specific NK-92 cell or cell line and to the ErbB2-specific NK-92 cell or cell line obtained or identified by the methods as well as their uses.
    Type: Application
    Filed: June 18, 2015
    Publication date: May 11, 2017
    Inventors: Winfried Wels, Kurt Schonfeld, Torsten Tonn, Manuel Grez, Congcong Zhang
  • INHIBITORS OF NHR2 AND/OR RUNX1/ETO-TETRAMERIZATION
    Publication number: 20160108031
    Abstract: The invention relates to inhibitors of the NHR2 tetramerization and their use as tumor therapeutics (e.g. against acute myeloid leukemia (AML)), cytostatics, and diagnostic agents.
    Type: Application
    Filed: April 25, 2014
    Publication date: April 21, 2016
    Applicant: Heinrich-Heine-Universitat Dusseldorf
    Inventors: Alexander Metz, Holger Gohlke, Julia Schanda, Christian Wichmann, Manuel Grez
  • STEM AND PROGENITOR CELL EXPANSION BY EVI, EVI-LIKE GENES AND SETBP1
    Publication number: 20090028836
    Abstract: A method of increasing cell proliferation by modulating levels of EVI and related genes. Activation of EVI-1, PRDM16, or SETBP1 can increase the proliferation rate, self renewal and/or in vitro and/or in vivo survival and/or engraftment of human cells, either in vitro or in vivo. The gene modulation can be performed by various means, including traditional cloning methods and retroviral-based gene activation methods. The method can also be used to more efficiently deliver gene-corrected cells to a patient in need of treatment.
    Type: Application
    Filed: November 30, 2007
    Publication date: January 29, 2009
    Inventors: Christof von Kalle, Manfred Schmidt, Manuel Grez
  • Expression of proteins in cord blood-derived endothelial cells
    Publication number: 20060034813
    Abstract: The invention provides a population of mature endothelial cells derived from human cord blood. The cells can be transduced with DNA encoding a therapeutically effective protein such as a blood coagulation factor. The cells are useful in a method for the production of a blood coagulation factor. They can further be used in hemophilia A or B gene therapy.
    Type: Application
    Filed: October 6, 2005
    Publication date: February 16, 2006
    Inventors: Christian Herder, Torsten Tonn, Manuel Grez, Erhard Seifried
  • HIV-1 virus isolates of a subtype and its differential diagnostics, a vaccine against HIV-1 virus infections of this subtype and method of producing same, use of the HIV-1 virus isolates
    Patent number: 6248328
    Abstract: Three new HIV-1 isolates HIV-1 D747(ECACC V92082718), HIV-1 D757(ECACC V92082719) and HIV-1 D760(ECACC V92082720) are disclosed, which represent a further independent subtype of the HIV-1 family and have been recovered from Indian patients which at the time when the virus was isolated showed no typical AIDS symptoms. Also disclosed are vaccines against HIV-1 infections by this subtype and a process for producing the same, as well as the use of the HIV-1 infection, as well as for differential diagnosis.
    Type: Grant
    Filed: February 25, 1999
    Date of Patent: June 19, 2001
    Assignee: Chemotherapeutisches Forschungsinstitut
    Inventors: Ursula Dietrich, Hagen Von Briesen, Manuel Grez, Helga Rubsamen-Waigmann
  • HIV-1 virus isolates of a subtype and its differential diagnostics
    Patent number: 5965135
    Abstract: Three new HIV-1 isolates HIV-1 D747(ECACC V92082718), HIV-1 D757(ECACC V92082719) and HIV-1 D760(ECACC V92082720) are disclosed, which represent a further independent subtype of the HIV-1 family and have been recovered from Indian patients which at the time when the virus was isolated showed no typical AIDS symptoms. Also disclosed are vaccines against HIV-1 infections by this subtype and a process for producing the same, as well as the use of the HIV-1 infection, as well as for differential diagnosis.
    Type: Grant
    Filed: April 20, 1995
    Date of Patent: October 12, 1999
    Assignee: Chemotherapeutisches Forschungsinstitut
    Inventors: Ursula Dietrich, Hagen Von Briesen, Manuel Grez, Helga Rubsamen-Waigmann